(0.86%) 5 248.49 points
(1.22%) 39 760 points
(0.51%) 16 400 points
(1.25%) $82.37
(1.05%) $1.736
(0.45%) $2 222.60
(-0.19%) $24.71
(0.99%) $918.75
(0.17%) $0.925
(0.51%) $10.82
(-0.04%) $0.791
(0.42%) $92.83
Live Chart Being Loaded With Signals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases...
Stats | |
---|---|
Today's Volume | 4.13M |
Average Volume | 15.23M |
Market Cap | 23.37M |
EPS | £0 ( 2023-09-27 ) |
Next earnings date | ( £0 ) 2024-04-25 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -1.740 |
ATR14 | £0.0160 (0.92%) |
Volume Correlation
Hemogenyx Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hemogenyx Pharmaceuticals Correlation - Currency/Commodity
Hemogenyx Pharmaceuticals Financials
Annual | 2022 |
Revenue: | £0 |
Gross Profit: | £-2.60M (0.00 %) |
EPS: | £-0.00440 |
Q2 | 2023 |
Revenue: | £0 |
Gross Profit: | £-319 909 (0.00 %) |
EPS: | £-0.00410 |
Q1 | 2023 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.00210 |
Q4 | 2022 |
Revenue: | £0 |
Gross Profit: | £-531 839 (0.00 %) |
EPS: | £-0.00290 |
Financial Reports:
No articles found.
Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators